Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Motorola Solutions EVP and CTO Mahesh Saptharishi Sells $1.53M of Stock
Mahesh Saptharishi, EVP and CTO, sold 2,998 shares of Motorola Solutions, Inc. at $511.08 to $515.24 a share (average $511.16) in 2 transactions, worth $1.53M in total on Nov 9, 2026. Shares held after the trade: 28,124 (-9.5%).
INVE Technologies reported Q3 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year due to the divestiture of its IoT business to Trackonomy. The company achieved GAAP net income of $0.6 million, driven by a gain on the asset sale, but currently has no commercial revenue following the transaction and is not providing future guidance.
Flowers Foods reported a significant increase in cash and cash equivalents to $72.2 million as of October 10, 2026, compared to $12.1 million at the start of the fiscal year. The company is currently executing strategic initiatives including an ERP system upgrade and the acquisition of Simple Mills while managing risks related to independent distributor partner classifications.
4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”
David Kirn, MD, Co-founder, President and Chief Executive Officer
Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.
Term
Q3 2026
“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant
For the nine months ended September 30, 2026, Evommune, Inc. reported a net loss of $84.8 million, more than double the $40.6 million loss in the prior year period, primarily driven by increased research and development and general and administrative expenses. Total assets grew to $278.3 million as of September 30, 2026, supported by cash and investments totaling approximately $262.3 million.
MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.
Term
Q3 2026
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”
Eric Risser, President and Chief Executive Officer
“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”
Eric Risser, President and Chief Executive Officer
Ouster Director Susan Heystee Sells $283K of Stock
Susan Heystee, Director, sold 7,551 shares of Ouster, Inc. at $37.44 a share, worth $283K in total on Nov 10, 2026. Shares held after the trade: 33,707 (-18.3%).
Precision Biosciences CLO Dario Scimeca Sells $27.5K of Stock
Dario Scimeca, CLO, sold 2,821 shares of Precision Biosciences Inc at $9.75 a share, worth $27.5K in total on Nov 10, 2026. Shares held after the trade: 56,782 (-4.7%).
Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.
Term
Q3 2026
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Martin Babler, President and Chief Executive Officer of Alumis
Cibus, Inc. reported financial results for the third quarter of 2026, highlighting progress in its rice herbicide-tolerance traits and the initiation of manufacturing for its first two biofragrance products. The company reduced its year-to-date cash usage by 19% year-over-year and expects to exit 2026 with an annualized net cash usage run rate of approximately $35 million.
Term
Q3 2026
“Three months ago I described three ways our platform creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Each of these moved closer this quarter. We received requests from our customer for larger quantities of two biofragrance products to advance their product development. Our Rice traits performed well in Latin American field trials and are now being tested where it counts, in our customer Interoc's own varieties in its own fields. Further, a second partner-funded crop program, Mustard in India, began work in the quarter.”
Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.
Chevron Vice Chairman Mark A. Nelson Sells $23.6M of Stock
Mark A. Nelson, Vice Chairman, sold 112,000 shares of Chevron Corp at $210.47 to $210.48 a share (average $210.48) in 2 transactions, worth $23.6M in total on Nov 10, 2026. Shares held after the trade: 11,647 (-72.1%).
LifeMD reported Q3 2026 revenue of $44.6 million and a GAAP net loss of $5.2 million, while improving adjusted EBITDA sequentially by $3.1 million. The company also announced it secured a $12.5 million senior secured term loan from Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund to replace its previous credit facility.
Term
Q3 2026
“We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing. We’re helping more people access high-quality healthcare, and we’re getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.”
Justin Schreiber, Chairman and CEO of LifeMD
“Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.”
PEDEVCO CORP reported a 1-for-20 reverse stock split effective March 13, 2026, which has been retroactively applied to all share data. As of November 9, 2026, the company had 13,282,934 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
On Semiconductor $1.75B Debt Financing with JPMorgan Chase Bank, N.A.
ON Semiconductor Corporation entered into an Amended and Restated Credit Agreement providing for a $1.75 billion senior revolving credit facility. The facility replaces a previous 2023 agreement and will be used for working capital, general corporate purposes, and financing permitted acquisitions. JPMorgan Chase Bank, N.A. serves as the administrative agent for a syndicate of major global lenders.
Ascend Wellness Holdings reported Q3 2026 net revenue of $130.0 million, a 4.2% year-over-year increase, driven by record retail transaction volumes. The company generated $31.1 million in Adjusted EBITDA and ended the quarter with 56 retail stores, subsequently expanding to 61 locations. Management highlighted strong operating leverage and positive cash flow from operations despite a significant semi-annual interest payment.
Term
Q3 2026
“Our third quarter results demonstrate the strength of our retail platform and the growing demand for our brands. We achieved record transaction volume and expanded our footprint ahead of schedule, positioning Ascend for continued growth as we optimize our operations and prepare for potential regulatory shifts in the industry.”
Hour Loop, Inc. reported net income of $2.30 million for the nine months ended September 30, 2026, on revenues of $95.95 million, representing an 11% revenue increase year-over-year. Despite higher sales, net income slightly decreased from $2.36 million in the prior year period due to increased cost of revenues and selling expenses.
Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”
Sergio Traversa, Chief Executive Officer of Relmada Therapeutics
“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”
Bipin Dalmia, Chief Business Officer of Relmada Therapeutics
OptimumBank Holdings reported Q3 2026 net income of $7.2 million, or $0.30 per diluted share, representing a 67% increase in EPS compared to the prior year. The company saw strong balance sheet growth with the gross loan portfolio increasing 12.3% sequentially to $1.37 billion and total deposits rising 10.6% to $1.34 billion.
Motorola Solutions SVP, Human Resources Kathryn A. Moore Sells $572K of Stock
Kathryn A. Moore, SVP, Human Resources, sold 1,080 shares of Motorola Solutions, Inc. at $529.19 to $529.43 a share (average $529.40) in 2 transactions, worth $572K in total on Nov 10, 2026. Shares held after the trade: 1,112 (-10.8%).
Fluent, Inc. reported Q3 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by a 100% growth in its Commerce Media Solutions segment. The company significantly reduced its net loss to $3.1 million from $7.6 million in the prior year and achieved breakeven Adjusted EBITDA.
Term
Q3 2026
“The third quarter was another strong quarter for us, driven by the continued growth of Commerce Media Solutions, which now represents 70% of our revenue and is operating at an annual revenue run rate that exceeds $145 million. Revenue from our aggregate continuing businesses grew 29% year-over-year in the third quarter, an acceleration from 25% in the second quarter. Commerce Media Solutions continues to reshape the profile of our Company. It is driving our growth, improving the quality of our revenue, and was a key contributor to delivering near-breakeven adjusted EBITDA this quarter.”
Don Patrick, Chief Executive Officer
“We continue to add new partners to our network, and we’re highly encouraged by the demand we’re seeing for our commerce media offerings across the markets we serve. As our revenue mix improves and our margin profile strengthens, we believe we are well positioned to close out a strong year. We remain confident in delivering full-year double-digit revenue growth on our aggregate continuing businesses with improved full-year adjusted EBITDA.”
GrabAGun Digital Holdings reported Q3 2026 net revenues of $21.2 million, a 4.7% decrease year-over-year due to lower product sales. Despite the revenue dip, gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, driven by improved sourcing and disciplined purchasing.
Term
Q3 2026
“Our third-quarter results reflect the progress we are making in improving the quality and profitability of our business. Gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, primarily driven by average selling prices and supported by better sourcing, a stronger product cost basis and disciplined purchasing.”
Marc Nemati, Chairman and Chief Executive Officer
“Subsequent to quarter end, we completed the acquisition of Camfour, a New England-based wholesale distributor funded entirely with cash on hand and without financing or issuing shares. We believe combining Camfour's distribution capabilities with our e-commerce and logistics platform will stimulate growth, expand our customer base and improve our purchasing economics.”
Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.
Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.
Liberty Latin America Insider Angoitia Alfonso De Buys $5.06M of Stock
Angoitia Alfonso De bought 249,214 shares of Liberty Latin America Ltd. at $20.22 to $20.30 a share (average $20.30) in 2 transactions, worth $5.06M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 725,565 (+51.1%).
United States Antimony Corp reported Q3 2026 revenue of $10.1 million, a 16% increase year-over-year, driven by a 68% surge in antimony pounds sold. Despite a 113% increase in gross profit to $4.3 million, the company reported a net loss of $9.5 million, impacted by non-cash stock-based compensation and an unrealized loss on its Larvotto Resources investment.
The Invesco Galaxy Ethereum ETF entered into a digital assets custody agreement with BNY Mellon to establish segregated accounts for the safekeeping of the Trust's ether holdings. The agreement has an initial five-year term and complements the Trust's existing custody arrangement with Coinbase. This move diversifies the Trust's custodial infrastructure for its underlying digital assets.
Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.
Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.
Value
$2.4M
Counterparty
NeuroAirmid Therapeutics, Inc.
“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”
Brian M. Culley, Lineage CEO
“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”
Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”
Bruce Steel, Chief Executive Officer of Equillium
“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
Snail, Inc. reported operational highlights for the third quarter of 2026, including 1.2 million units sold of ARK: Survival Ascended and 559,000 units of ARK: Survival Evolved. The company also highlighted the launch of several new titles including Honeycomb: The World Beyond and Stoneguard, alongside the debut of its AI gaming companion initiative, Non-Human Player (NHP).